TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter.

Turaj, Anna H; Dahal, Lekh N; Beers, Stephen A; Cragg, Mark S; Lim, Sean H

Turaj, Anna H; Dahal, Lekh N; Beers, Stephen A; Cragg, Mark S; Lim, Sean H.

Afiliación

Turaj AH; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Dahal LN; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Beers SA; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Cragg MS; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Lim SH; Antibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom. s.h.lim@soton.ac.uk.

Cancer Res ; 77(12): 3376-3378, 2017 06 15.

Article en En | MEDLINE | ID: mdl-28584185

Asunto(s)

Receptores Toll-Like; Trastuzumab; Humanos; Receptor ErbB-2

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptores Toll-Like / Trastuzumab Límite: Humans Idioma: En Revista: Cancer Res Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google